Medtronic (NYSE:MDT – Free Report) had its price objective lowered by Stifel Nicolaus from $105.00 to $95.00 in a research note published on Monday morning,MarketScreener reports. Stifel Nicolaus currently has a hold rating on the medical technology company’s stock.
Several other equities analysts have also commented on the company. Citigroup dropped their target price on Medtronic from $117.00 to $110.00 and set a “buy” rating on the stock in a report on Tuesday. William Blair raised Medtronic from a “market perform” rating to an “outperform” rating in a report on Tuesday, January 6th. Wall Street Zen raised Medtronic from a “hold” rating to a “buy” rating in a report on Saturday, March 28th. Truist Financial dropped their target price on Medtronic from $107.00 to $103.00 and set a “hold” rating on the stock in a report on Wednesday, February 18th. Finally, Robert W. Baird dropped their target price on Medtronic from $103.00 to $100.00 and set a “neutral” rating on the stock in a report on Wednesday, February 18th. One research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Medtronic has an average rating of “Moderate Buy” and a consensus price target of $109.10.
Check Out Our Latest Stock Analysis on MDT
Medtronic Stock Up 2.6%
Medtronic (NYSE:MDT – Get Free Report) last announced its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.34 by $0.02. The business had revenue of $9.02 billion for the quarter, compared to analysts’ expectations of $8.89 billion. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The company’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same period last year, the firm earned $1.38 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, equities analysts predict that Medtronic will post 5.46 EPS for the current fiscal year.
Medtronic Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Friday, April 17th. Shareholders of record on Friday, March 27th will be issued a dividend of $0.71 per share. The ex-dividend date of this dividend is Friday, March 27th. This represents a $2.84 annualized dividend and a dividend yield of 3.2%. Medtronic’s dividend payout ratio (DPR) is presently 79.11%.
Insider Activity
In other Medtronic news, EVP Harry Skip Kiil sold 52,524 shares of the firm’s stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the transaction, the executive vice president owned 32,768 shares of the company’s stock, valued at approximately $3,201,761.28. This trade represents a 61.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.26% of the company’s stock.
Hedge Funds Weigh In On Medtronic
Several hedge funds have recently made changes to their positions in the company. Curbstone Financial Management Corp grew its holdings in shares of Medtronic by 1.8% during the fourth quarter. Curbstone Financial Management Corp now owns 5,594 shares of the medical technology company’s stock worth $537,000 after buying an additional 100 shares during the last quarter. New England Capital Financial Advisors LLC grew its holdings in shares of Medtronic by 7.8% during the fourth quarter. New England Capital Financial Advisors LLC now owns 1,403 shares of the medical technology company’s stock worth $135,000 after buying an additional 101 shares during the last quarter. Ipsen Advisor Group LLC grew its holdings in shares of Medtronic by 1.7% during the fourth quarter. Ipsen Advisor Group LLC now owns 5,952 shares of the medical technology company’s stock worth $572,000 after buying an additional 101 shares during the last quarter. Quadrant Capital Group LLC grew its holdings in shares of Medtronic by 0.3% during the fourth quarter. Quadrant Capital Group LLC now owns 32,477 shares of the medical technology company’s stock worth $3,120,000 after buying an additional 101 shares during the last quarter. Finally, Baker Tilly Wealth Management LLC grew its holdings in shares of Medtronic by 3.3% during the fourth quarter. Baker Tilly Wealth Management LLC now owns 3,221 shares of the medical technology company’s stock worth $309,000 after buying an additional 102 shares during the last quarter. Hedge funds and other institutional investors own 82.06% of the company’s stock.
Key Medtronic News
Here are the key news stories impacting Medtronic this week:
- Positive Sentiment: FDA clearance expands robotic/surgical addressable market — Medtronic received U.S. FDA clearance for its AI-enabled Stealth AXiS system for cranial and ENT procedures, extending the platform beyond spine and broadening opportunities in computer-assisted and robotic surgery. This is a clear product-side growth catalyst for surgical robotics and navigation adoption. Assessing Medtronic Valuation After Stealth AXiS FDA Clearance
- Positive Sentiment: Market tailwinds in core device markets — industry reports highlight multi-year growth in anesthesia/respiratory and lung-cancer surgery markets, with Medtronic named among leading vendors; these secular trends support steady revenue opportunities for MDT’s device franchises. Anesthesia & Respiratory Market Report Lung Cancer Surgery Market
- Neutral Sentiment: Investor note and price action coverage — market write-ups (e.g., Zacks) point to MDT’s intraday move and recent momentum; useful for short-term sentiment tracking but largely descriptive. Zacks: What Investors Need to Know
- Neutral Sentiment: Mixed analyst adjustments — several firms trimmed price targets (Evercore, Citi, others) but mostly kept positive/neutral ratings (buy/outperform/hold). That leaves medium-term upside in some models but increases short-term uncertainty. Evercore PT Adjustment Citi PT Adjustment
- Negative Sentiment: Stifel trims target citing MiniMed IPO impacts — Stifel cut its price target to $95 and flagged transaction-related effects from the recent MiniMed IPO as a reason for lowering near-term expectations; that raises near-term analyst-model risk and may weigh on sentiment. Stifel Cuts MDT Target to $95
- Negative Sentiment: Competitive pressure in cardiac rhythm devices — Johnson & Johnson launched an enhanced pulsed-field ablation device in Europe, signaling faster product rollouts from competitors in electrophysiology that could pressure share gains in select cardiac franchises. J&J launches enhanced PFA device
Medtronic Company Profile
Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.
Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).
See Also
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.
